Adaptimmune Therapeutics Plc Market Cap ($9.54 Million)
Market Cap & Net Worth: Adaptimmune Therapeutics Plc (ADAP)
Adaptimmune Therapeutics Plc market cap. Adaptimmune Therapeutics Plc (NASDAQ:ADAP) has a market capitalization of $9.54 Million ($9.54 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27060 globally and #5623 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adaptimmune Therapeutics Plc's stock price $0.04 by its total outstanding shares 265051591 (265.05 Million). Also see cash efficiency ratio of Adaptimmune Therapeutics Plc for how efficiently the company converts equity into cash flow.
Adaptimmune Therapeutics Plc Market Cap History (2015–2025)
Adaptimmune Therapeutics Plc market cap history from 2015 to 2025. Data shows change from $3.20 Billion to $9.54 Million (-41.72% CAGR). Check Adaptimmune Therapeutics Plc (ADAP) stock price for real-time trading data and today's change.
Index Memberships
Adaptimmune Therapeutics Plc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #755 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2470 of 3165 |
Weight: Adaptimmune Therapeutics Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adaptimmune Therapeutics Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adaptimmune Therapeutics Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ADAP year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.80x
Adaptimmune Therapeutics Plc's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.20 Billion | $10.72 Million | -$21.59 Million | 298.15x | N/A |
| 2016 | $1.07 Billion | $14.20 Million | -$71.58 Million | 75.61x | N/A |
| 2017 | $1.77 Billion | $37.83 Million | -$70.14 Million | 46.80x | N/A |
| 2018 | $1.52 Billion | $59.51 Million | -$95.51 Million | 25.61x | N/A |
| 2019 | $318.06 Million | $1.12 Million | -$137.16 Million | 283.48x | N/A |
| 2020 | $1.43 Billion | $3.96 Million | -$130.09 Million | 360.95x | N/A |
| 2021 | $993.94 Million | $6.15 Million | -$158.09 Million | 161.64x | N/A |
| 2022 | $386.98 Million | $27.15 Million | -$165.46 Million | 14.25x | N/A |
| 2023 | $210.19 Million | $60.28 Million | -$113.87 Million | 3.49x | N/A |
| 2024 | $142.78 Million | $178.03 Million | -$70.81 Million | 0.80x | N/A |
Competitor Companies of ADAP by Market Capitalization
Companies near Adaptimmune Therapeutics Plc in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Adaptimmune Therapeutics Plc for a full breakdown of the balance sheet.
Key companies related to Adaptimmune Therapeutics Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Adaptimmune Therapeutics Plc (2015–2025)
Market capitalization of Adaptimmune Therapeutics Plc from 2015 to today. Between 2015 and today, Adaptimmune Therapeutics Plc's market cap moved from $3.20 Billion to $ 9.54 Million, with a yearly change of -41.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $9.54 Million | -93.32% |
| 2024 | $142.78 Million | -32.07% |
| 2023 | $210.19 Million | -45.68% |
| 2022 | $386.98 Million | -61.07% |
| 2021 | $993.94 Million | -30.43% |
| 2020 | $1.43 Billion | +349.17% |
| 2019 | $318.06 Million | -79.13% |
| 2018 | $1.52 Billion | -13.92% |
| 2017 | $1.77 Billion | +64.94% |
| 2016 | $1.07 Billion | -66.42% |
| 2015 | $3.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Adaptimmune Therapeutics Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.54 Million USD |
| MoneyControl | $9.54 Million USD |
| MarketWatch | $9.54 Million USD |
| marketcap.company | $9.54 Million USD |
| Reuters | $9.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more